Cognition Therapeutics’ (CGTX) Buy Rating Reiterated at Chardan Capital

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a report released on Thursday,Benzinga reports. They presently have a $11.00 price target on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Cognition Therapeutics in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $8.20.

Cognition Therapeutics Trading Up 27.5 %

Shares of Cognition Therapeutics stock opened at $0.58 on Thursday. The stock’s fifty day moving average price is $0.47 and its 200-day moving average price is $0.94. The firm has a market cap of $24.10 million, a P/E ratio of -0.60 and a beta of 1.26. Cognition Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.95.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. CM Management LLC boosted its stake in Cognition Therapeutics by 14.3% in the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after acquiring an additional 25,000 shares in the last quarter. Sigma Planning Corp increased its position in shares of Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Cognition Therapeutics in the 3rd quarter worth $27,000. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.